We are live on ! Find out more
IBB icon

iShares Biotechnology ETF
IBB

Fund managers haven’t disclosed any holdings of IBB yet.

IBB Hedge Fund Activity: Q1 2026 in Review

917 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2026, worth a combined $7.03B — up 1.4% from $6.94B a quarter earlier.

Sellers outnumbered buyers: 92 funds closed out of IBB and 68 opened new positions — a net loss of 24 holders — while 288 trimmed existing stakes and 270 added.

The largest buyer was JP Morgan Chase, adding an estimated $361M. The largest seller was Two Sigma Investments, cutting an estimated $157M.

  • 917 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2026, down from 955 in Q4 2025.
  • Funds reported $7.03B of iShares Biotechnology ETF stock for Q1 2026, up 1.4% quarter-over-quarter.
  • 68 funds opened new iShares Biotechnology ETF positions in Q1 2026 and 92 closed out, a net change of -24 holders.
  • The largest iShares Biotechnology ETF buyer in Q1 2026 was JP Morgan Chase, an estimated $361M added.
  • The largest iShares Biotechnology ETF seller in Q1 2026 was Two Sigma Investments, an estimated $157M sold.

Based on aggregated 13F filings for Q1 2026.